Efficacy of Shenqi Pollen Capsules for High-Altitude Deacclimatization Syndrome via Suppression of the Reoxygenation Injury and Inflammatory Response
Table 3
Analysis of symptom incidences of HADAS.
Symptoms
Baseline
Week 7
Week 14
Placebo group ()
SPC group ()
value
Placebo group ()
SPC group ()
RR
value
Placebo group ()
SPC group ()
RR
value
Sleepiness
97 (68.30%)
87 (59.58%)
0.13
50 (35.21%)
35 (23.97%)
0.58
0.04
23 (16.20%)
9 (6.16%)
0.34
0.009
Insomnia
60 (42.25%)
62 (42.46%)
0.94
44 (30.99%)
26 (17.81%)
0.51
0.02
26 (18.31%)
10 (10.96%)
0.44
0.03
Unresponsiveness
93 (65.49%)
100 (68.49%)
0.63
60 (42.25%)
44 (30.13%)
0.58
0.03
29 (20.42%)
14 (9.59%)
0.47
0.04
Memory loss
86 (60.56%)
88 (60.27%)
0.99
59 (41.54%)
41 (28.08%)
0.55
0.02
28 (19.72%)
17 (11.64%)
0.70
0.28
Agitation
52 (36.61%)
45 (30.82%)
0.27
27 (19.01%)
15 (10.27%)
0.49
0.04
15 (10.56%)
10 (6.85%)
0.58
0.23
Headache
66 (46.47%)
67 (45.89%)
0.97
44 (33.10%)
32 (21.91%)
0.58
0.04
23 (16.20%)
12 (8.22%)
0.46
0.04
Dizziness
100 (70.42%)
111 (79.02%)
0.28
67 (47.18%)
47 (32.19%)
0.53
0.01
44 (30.99%)
18 (12.33%)
0.42
0.004
Throat pain or discomfort
50 (35.21%)
43 (29.45%)
0.26
24 (16.90%)
25 (17.12%)
1.06
0.87
12 (8.45%)
13 (8.90%)
1.40
0.41
Coughing
97 (68.30%)
114 (78.08%)
0.06
57 (40.14%)
40 (27.39%)
0.54
0.02
31 (21.83%)
11 (7.53%)
0.42
0.01
Expectoration
68 (47.88%)
68 (46.57%)
0.75
28 (19.72%)
27 (18.49%)
0.90
0.74
19 (13.38%)
6 (4.11%)
0.38
0.03
Chest tightness
64 (45.07%)
55 (37.67%)
0.18
41 (28.87%)
24 (16.43%)
0.47
0.01
17 (11.97%)
7 (4.79%)
0.37
0.03
Flustering
82 (57.74%)
74 (50.68%)
0.25
52 (36.61%)
36 (24.66%)
0.57
0.03
28 (19.72%)
13 (8.90%)
0.47
0.02
Increased appetite
68 (47.88%)
67 (45.89%)
0.77
49 (34.51%)
35 (21.91%)
0.60
0.05
22 (15.49%)
9 (6.16%)
0.51
0.08
Decreased appetite
58 (40.84%)
56 (38.35%)
0.64
44 (30.99%)
32 (21.92%)
0.60
0.06
21 (14.79%)
8 (5.48%)
0.32
0.009
Diarrhea
66 (46.47%)
50 (36.98%)
0.10
22 (15.49%)
25 (17.12%)
1.12
0.73
8 (5.63%)
0 (0.00%)
0.10
0.03
Abdominal distention
48 (33.80%)
50 (34.24%)
0.97
37 (26.06%)
23 (15.75%)
0.97
0.99
12 (8.45%)
8 (5.48%)
0.71
0.46
Abdominal pain
37 (26.05%)
35 (23.97%)
0.71
19 (13.38%)
14 (9.59%)
1.11
0.71
5 (3.52%)
1 (0.07%)
0.17
0.12
Lumbago
50 (35.21%)
42 (28.76%)
0.23
23 (16.19%)
24 (16.43%)
1.37
0.23
17 (11.97%)
14 (11.64%)
0.77
0.51
Arthralgia
68 (47.88%)
61 (41.78%)
0.35
25 (17.61%)
24 (16.44%)
1.25
0.35
19 (13.38%)
11 (7.53%)
0.56
0.14
The data are presented as the number (%) of subjects. RR represents the relative risk for the SPC versus the placebo group. The symptom incidences were compared using Fisher’s exact tests.
